Baylor Genome Center Standardizes on Roche NimbleGen Exome Capture Technology for Human Disease Studies

08.2010 – The Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has standardized its target enrichment human disease research studies on Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More t

Researchers Solve Mystery of Uner Tan Syndrome with Targeted Next-Generation Sequencing Using Roche NimbleGen Sequence Capture and 454 Sequencing Systems

07.2010 – A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche (SIX: RO, ROG; OTCQX: RHHBY). The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery. The study was presented by Suleyman Gulsuner, M.D. f

Results from Two Multi-Site Collaborative Studies Highlight the Value of 454 Sequencing Systems for Genotyping Applications

07.2010 – 454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), has announced promising new results from a multi-site collaborative research study which used the company-s Genome Sequencer FLX System to perform HIV drug-resistant mutation detection. The findings were outlined last month at the International HIV & Hepatitis Virus Drug Resistance Workshop in Dubrovnik, Croatia, and follow only weeks after the results from a similar multi-site research study, which used the company-s